{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:30:21Z","timestamp":1764333021235},"reference-count":4,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Imperial College Healthcare NHS Trust Infection"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We report a 59-year-old male with left leg osteomyelitis caused by an XDR Pseudomonas aeruginosa strain following a road traffic accident. Limited treatment options and adverse antimicrobial reaction led to consideration of cefiderocol together with appropriate surgical intervention. Improved bony remodelling over the tibia and fibula was observed with good bony alignment and no adverse features. Physiotherapy support was continued for 4\u2009months following treatment, which resulted in good functional mobility, improved proprioception and full ability to bear weight. This case also adds to multiple reports that describe safe and successful use of cefiderocol to treat MDR, aerobic Gram-negative infections. The prescribing information for cefiderocol is available at: https:\/\/shionogi-eu-content.com\/gb\/fetcroja\/pi.<\/jats:p>","DOI":"10.1093\/jacamr\/dlab054","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:03:42Z","timestamp":1618445022000},"page":"i18-i20","source":"Crossref","is-referenced-by-count":8,"title":["<i>Education:<\/i> A compassionate use of cefiderocol to treat osteomyelitis caused by an XDR <i>Pseudomonas aeruginosa<\/i>"],"prefix":"10.1093","volume":"3","author":[{"given":"A","family":"Chavda","sequence":"first","affiliation":[{"name":"Imperial College Healthcare NHS Trust, St Mary\u2019s Hospital, London W2 1NY, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Gilchrist","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust, St Mary\u2019s Hospital, London W2 1NY, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Samarasinghe","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust, St Mary\u2019s Hospital, London W2 1NY, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,6,15]]},"reference":[{"key":"2021082617410066600_dlab054-B1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/ki.2014.328","article-title":"The definition of acute kidney injury and its use in practice","volume":"87","author":"Thomas","year":"2015","journal-title":"Kidney Int"},{"key":"2021082617410066600_dlab054-B2","doi-asserted-by":"crossref","first-page":"ofaa150","DOI":"10.1093\/ofid\/ofaa150","article-title":"Case report: successful rescue therapy of extensively drug-resistant Acinetobacter baumannii osteomyelitis with cefiderocol","volume":"7","author":"Dagher","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2021082617410066600_dlab054-B3","doi-asserted-by":"crossref","first-page":"e01872","DOI":"10.1128\/AAC.01872-19","article-title":"Long-term compassionate use of cefiderocol to treat chronic osteomyelitis caused by extensively drug-resistant Pseudomonas aeruginosa and extended-spectrum-\u03b2-lactamase-producing Klebsiella pneumoniae in a pediatric patient","volume":"64","author":"Alamarat","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2021082617410066600_dlab054-B4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40121-020-00286-6","article-title":"Cefiderocol: a novel agent for the management of multidrug-resistant Gram-negative organisms","volume":"9","author":"Wu","year":"2020","journal-title":"Infect Dis Ther"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jacamr\/article-pdf\/3\/Supplement_1\/i18\/39990380\/dlab054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jacamr\/article-pdf\/3\/Supplement_1\/i18\/39990380\/dlab054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T17:41:54Z","timestamp":1629999714000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/3\/Supplement_1\/i18\/6299847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":4,"journal-issue":{"issue":"Supplement_1","published-print":{"date-parts":[[2021,6,15]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlab054","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2021,6,1]]}}}